People · Operator
Named in public records as an officer, director or promoter · active 2011–2019 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Proclara Biosciences, Inc. | — | Biotechnology | Series C | $76.8M | $283.6M | 2011 |
| Octagon Therapeutics, Inc. | — | Pharmaceuticals | Series A | $12.4M | $68.3M | 2018 |
| Hydra Biosciences Inc | — | Biotechnology | Series A | $10.5M | $379.9M | 2015 |
Paul Goldenheim at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Goldenheim on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Lynch | 1 | 7 |
| Jean George | 1 | 6 |
| Vicki Sato | 1 | 6 |
| Nick Leschly | 1 | 5 |
| Thorne Sparkman | 1 | 5 |
| Robert Carpenter | 1 | 5 |
| Steven E. Hall | 1 | 4 |
| Tom Burke | 1 | 3 |
| Jonathan Solomon | 1 | 3 |
| Ronald Lennox | 1 | 3 |
| Isaac Stoner | 1 | 2 |
| Francois Valencony | 1 | 1 |
| Peter Smedvig | 1 | 1 |
| Nico Dosenbach | 1 | 1 |
| John Dee | 1 | 1 |
| Kenneth Buckfire | 1 | 1 |
| Mark Skaletsky | 1 | 1 |
| Valerie Calenda | 1 | 1 |
| Hampus Hillerstrom | 1 | 1 |
| Fred Ausubel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.